Oclacitinib, a Janus Kinase Inhibitor, Reduces the Frequency of IL-4- and IL-10-, but Not IFN-γ-, Producing Murine CD4 and CD8 T Cells and Counteracts the Induction of Type 1 Regulatory T Cells

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2021 Sep 28

PMID 34577127

Citations 4

Authors

Agnieszka Jasiecka-Mikolajczyk

Jerzy J Jaroszewski

Tomasz Maslanka

Affiliations

Soon will be listed here.

Abstract

The purpose of the present study was to broaden the knowledge and understanding of the effects of oclacitinib (OCL), a Janus kinase inhibitor, on T cells in the context of both the immune mechanisms underlying anti-inflammatory and anti-allergic properties of the drug and its safety. The results indicate that beneficial effects of OCL in the treatment of skin allergic diseases may be partially mediated by the inhibition of IL-4 production in CD4 and CD8 T cells. To a certain extent, the antiproliferative effect of OCL on CD8 T cells may also contribute to its therapeutic effect. The study found that OCL does not affect the proliferation of CD4 T cells or the number of IFN-γ- and IL-17-producing CD4 and CD8 T cells. Moreover, OCL was found to counteract the induction of type 1 regulatory T (Tr1) cells and to act as a strong inhibitor of IL-10 production in both CD4 and CD8 T cells. Thus, these results indicate that beneficial effects of OCL in the treatment of skin allergic diseases are not mediated through: (a) the abolishment of IFN-γ and IL-17-production in CD4 and CD8 T cells; (b) generation of Tr1 cells; (c) inhibition of CD4 T cell proliferation; (d) induction of IL-10 production in CD4 T cells. The results of this study strongly suggest that, with respect to the evaluated parameters, OCL exerts a suppressive effect on Th2- but not Th1-mediated immunity.

Citing Articles

Treatment with oclacitinib, a Janus kinase inhibitor, down-regulates and up-regulates CD25 and Foxp3 expression, respectively, in peripheral blood T cells of dogs with atopic dermatitis.

Jasiecka-Mikolajczyk A, Socha P BMC Vet Res. 2024; 20(1):489.

PMID: 39462373 PMC: 11515184. DOI: 10.1186/s12917-024-04340-0.

CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential.

Koh C, Lee S, Kwak M, Kim B, Chung Y Exp Mol Med. 2023; 55(11):2287-2299.

PMID: 37907738 PMC: 10689838. DOI: 10.1038/s12276-023-01105-x.

Immunological characteristics of CD103CD8 Tc cells in the liver of C57BL/6 mouse infected with plasmodium NSM.

Shi F, Tang S, Chen D, Mo F, Li J, Fang C Parasitol Res. 2023; 122(11):2513-2524.

PMID: 37707607 DOI: 10.1007/s00436-023-07950-z.

Effect of IL-27, Teriflunomide and Retinoic Acid and Their Combinations on CD4 T Regulatory T Cells-An In Vitro Study.

Maslanka T Molecules. 2022; 27(23).

PMID: 36500570 PMC: 9739213. DOI: 10.3390/molecules27238471.

References

Yang X, Ghoreschi K, Steward-Tharp S, Rodriguez-Canales J, Zhu J, Grainger J . Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol. 2011; 12(3):247-54. PMC: 3182404. DOI: 10.1038/ni.1995. View

Carmi-Levy I, Homey B, Soumelis V . A modular view of cytokine networks in atopic dermatitis. Clin Rev Allergy Immunol. 2011; 41(3):245-53. DOI: 10.1007/s12016-010-8239-6. View

Pot C, Apetoh L, Awasthi A, Kuchroo V . Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27. Semin Immunol. 2011; 23(6):438-45. PMC: 3230686. DOI: 10.1016/j.smim.2011.08.003. View

Barrat F, Cua D, Boonstra A, Richards D, Crain C, Savelkoul H . In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med. 2002; 195(5):603-16. PMC: 2193760. DOI: 10.1084/jem.20011629. View

Carter L, Murphy K . Lineage-specific requirement for signal transducer and activator of transcription (Stat)4 in interferon gamma production from CD4(+) versus CD8(+) T cells. J Exp Med. 1999; 189(8):1355-60. PMC: 2193026. DOI: 10.1084/jem.189.8.1355. View

Kaplan M, Wurster A, Grusby M . A signal transducer and activator of transcription (Stat)4-independent pathway for the development of T helper type 1 cells. J Exp Med. 1998; 188(6):1191-6. PMC: 2212539. DOI: 10.1084/jem.188.6.1191. View

Wang H, Brown J, Gao S, Liang S, Jotwani R, Zhou H . The role of JAK-3 in regulating TLR-mediated inflammatory cytokine production in innate immune cells. J Immunol. 2013; 191(3):1164-74. PMC: 3720823. DOI: 10.4049/jimmunol.1203084. View

Chihara N, Madi A, Karwacz K, Awasthi A, Kuchroo V . Differentiation and Characterization of Tr1 Cells. Curr Protoc Immunol. 2016; 113:3.27.1-3.27.10. PMC: 5933847. DOI: 10.1002/0471142735.im0327s113. View

Chen L, Chen G, Zhang M, Xiong X, Liu H, Xin J . Imbalance between subsets of CD8(+) peripheral blood T cells in patients with chronic obstructive pulmonary disease. PeerJ. 2016; 4:e2301. PMC: 4975138. DOI: 10.7717/peerj.2301. View

10.

Gonzales A, Fleck T, Humphrey W, Galvan B, Aleo M, Mahabir S . IL-31-induced pruritus in dogs: a novel experimental model to evaluate anti-pruritic effects of canine therapeutics. Vet Dermatol. 2015; 27(1):34-e10. PMC: 4737310. DOI: 10.1111/vde.12280. View

11.

Tousa S, Semitekolou M, Morianos I, Banos A, Trochoutsou A, Brodie T . Activin-A co-opts IRF4 and AhR signaling to induce human regulatory T cells that restrain asthmatic responses. Proc Natl Acad Sci U S A. 2017; 114(14):E2891-E2900. PMC: 5389328. DOI: 10.1073/pnas.1616942114. View

12.

Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M . The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. 2017; 15(1):23. PMC: 5480189. DOI: 10.1186/s12964-017-0177-y. View

13.

Chiricozzi A, Maurelli M, Peris K, Girolomoni G . Targeting IL-4 for the Treatment of Atopic Dermatitis. Immunotargets Ther. 2020; 9:151-156. PMC: 7532907. DOI: 10.2147/ITT.S260370. View

14.

Kulling P, Olson K, Hamele C, Toro M, Tan S, Feith D . Dysregulation of the IFN-γ-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. PLoS One. 2018; 13(2):e0193429. PMC: 5825082. DOI: 10.1371/journal.pone.0193429. View

15.

Boyman O, Werfel T, Akdis C . The suppressive role of IL-10 in contact and atopic dermatitis. J Allergy Clin Immunol. 2011; 129(1):160-1. DOI: 10.1016/j.jaci.2011.10.046. View

16.

Maeda S, Tsuchida H, Marsella R . Allergen challenge decreases mRNA expression of regulatory cytokines in whole blood of high-IgE beagles. Vet Dermatol. 2007; 18(6):422-6. DOI: 10.1111/j.1365-3164.2007.00630.x. View

17.

Amado T, Amorim A, Enguita F, Romero P, Inacio D, de Miranda M . MicroRNA-181a regulates IFN-γ expression in effector CD8 T cell differentiation. J Mol Med (Berl). 2020; 98(2):309-320. PMC: 7007887. DOI: 10.1007/s00109-019-01865-y. View

18.

Arican O, Aral M, Sasmaz S, Ciragil P . Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005; 2005(5):273-9. PMC: 1533889. DOI: 10.1155/MI.2005.273. View

19.

Koning H, Neijens H, Baert M, Oranje A, Savelkoul H . T cells subsets and cytokines in allergic and non-allergic children. II. Analysis and IL-5 and IL-10 mRNA expression and protein production. Cytokine. 1997; 9(6):427-36. DOI: 10.1006/cyto.1996.0185. View

20.

Olivry T, Naydan D, Moore P . Characterization of the cutaneous inflammatory infiltrate in canine atopic dermatitis. Am J Dermatopathol. 1997; 19(5):477-86. DOI: 10.1097/00000372-199710000-00008. View